Abstract: Pemphigus Vulgaris (PV) is a mucocutaneous blistering disorder characterized by pathogenic autoantibodies against desmogleins 1 and 3. The etiology of pemphigus vulgaris is unknown, but patients are at risk that has a genetic predisposition. Several studies have linked PV with human leukocyte antigen (HLA). In addition to diet, stress, viral infections, medications, radiation therapy, and allergens, environmental factors may induce immune dysregulation, leading to a flare of PV. Systemic corticosteroids have significantly impacted the treatment of pemphigus vulgaris and remain the backbone in the management of PV. Anti-CD20 monoclonal antibodies, such as rituximab and ofatumumab, have also been used with corticosteroids for first-line treatment in moderate-to-severe pemphigus. This study aims to review the efficacy of corticosteroid (CS) versus rituximab for PV.
Keywords: Corticosteroid, Efficacy, Pemphigus Vulgaris, Rituximab.
Title: Efficacy of Corticosteroid Versus Rituximab For Pemphigus Vulgaris: A Literature Review
Author: Elrica Stella Octaviani, Arin Armini, Luh Putu Dina Wahyuni
International Journal of Healthcare Sciences
ISSN 2348-5728 (Online)
Vol. 11, Issue 2, October 2023 - March 2024
Page No: 30-33
Research Publish Journals
Website: www.researchpublish.com
Published Date: 02-November-2023
